Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $526 to $587.
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $526 to $587.